Olivia Maleux1, Vincent Vander Poorten1,2, Robert Hermans3, Greet Hens1,4, Geert Maleux5. 1. Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium. 2. Oncology, Section Head and Neck Oncology, University Hospitals Leuven, Leuven, Belgium. 3. Head and Neck Radiology, University Hospitals Leuven, Leuven, Belgium. 4. Neurosciences, Section Experimental Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium. 5. Interventional Radiology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. geert.maleux@uzleuven.be.
Abstract
OBJECTIVE: To evaluate the safety and efficacy of percutaneous doxycycline sclerotherapy of head and neck lymphatic malformations (LM) with a 40-month follow-up of 27 cases. MATERIALS AND METHODS: Twenty-seven consecutive patients with head and neck LM who underwent doxycycline sclerotherapy from 2010 to 2019 were retrospectively reviewed. Pre- and peri-interventional data collection included patients' demographics, clinical and radiological presentation, number of treatment procedures, amount of doxycycline used for each session of sclerotherapy. Postinterventional clinical outcome data were assessed based on the electronic, medical reports with special attention to clinical improvement, measurement of the lesion on ultrasound and magnetic resonance imaging after the last session of sclerotherapy and complications of sclerotherapy. RESULTS: Twenty-seven patients underwent a mean of four doxycycline sclerotherapy sessions (range 1-23). The mean total dose of injected doxycycline per session was 170 mg. Maximal diameter of the LM decreased from mean 59.7 mm (median 58 mm; 25-130 mm) before treatment to mean of 29.6 mm (median 30 mm; 0 mm 64 mm) after the last session (P < 0.0001). Over a mean follow-up period of 40 months, complete or incomplete disappearance of symptoms was found in 23 (85%) and 3 (11%) of patients, respectively. In one patient, sclerotherapy did not result in better clinical outcome. Two out of 27 patients presented with minor post-procedural complications, and one patient with a post-procedural intralesional bleeding considered as a major complication. CONCLUSION: Ultrasound-guided, percutaneous doxycycline sclerotherapy is a safe and effective method of managing symptomatic LM of the head and neck.
OBJECTIVE: To evaluate the safety and efficacy of percutaneous doxycycline sclerotherapy of head and neck lymphatic malformations (LM) with a 40-month follow-up of 27 cases. MATERIALS AND METHODS: Twenty-seven consecutive patients with head and neck LM who underwent doxycycline sclerotherapy from 2010 to 2019 were retrospectively reviewed. Pre- and peri-interventional data collection included patients' demographics, clinical and radiological presentation, number of treatment procedures, amount of doxycycline used for each session of sclerotherapy. Postinterventional clinical outcome data were assessed based on the electronic, medical reports with special attention to clinical improvement, measurement of the lesion on ultrasound and magnetic resonance imaging after the last session of sclerotherapy and complications of sclerotherapy. RESULTS: Twenty-seven patients underwent a mean of four doxycycline sclerotherapy sessions (range 1-23). The mean total dose of injected doxycycline per session was 170 mg. Maximal diameter of the LM decreased from mean 59.7 mm (median 58 mm; 25-130 mm) before treatment to mean of 29.6 mm (median 30 mm; 0 mm 64 mm) after the last session (P < 0.0001). Over a mean follow-up period of 40 months, complete or incomplete disappearance of symptoms was found in 23 (85%) and 3 (11%) of patients, respectively. In one patient, sclerotherapy did not result in better clinical outcome. Two out of 27 patients presented with minor post-procedural complications, and one patient with a post-procedural intralesional bleeding considered as a major complication. CONCLUSION: Ultrasound-guided, percutaneous doxycycline sclerotherapy is a safe and effective method of managing symptomatic LM of the head and neck.
Authors: Kevin M Motz; Katherine B Nickley; Joshua R Bedwell; Bhupender Yadav; Philip C Guzzetta; Albert K Oh; Nancy M Bauman Journal: Ann Otol Rhinol Laryngol Date: 2014-02 Impact factor: 1.547
Authors: Sophie E R Horbach; Max M Lokhorst; Peerooz Saeed; Claire M F de Goüyon Matignon de Pontouraude; Aniki Rothová; Chantal M A M van der Horst Journal: J Plast Reconstr Aesthet Surg Date: 2015-11-18 Impact factor: 2.740
Authors: Simone J Boardman; Lesley A Cochrane; Derek Roebuck; Martin J Elliott; Benjamin E J Hartley Journal: Arch Otolaryngol Head Neck Surg Date: 2010-03
Authors: Patricia E Burrows; Ragheed K Mitri; Ahmad Alomari; Horacio M Padua; David J Lord; Mary Beth Sylvia; Steven J Fishman; John B Mulliken Journal: Lymphat Res Biol Date: 2008 Impact factor: 2.589